Genomic Track

27th November – 10:00 – 11:15 – Session IV
Education Track

Why Should the EU Take a Lead?

Europe is well positioned to lead in personalised medicine, underpinned by a:

  • Large and heterogenous population, encompassing those with diverse ethnic populations as well as a number of genetic isolate populations. This gives capability of ensuring diversity and all the equality and scientific benefits that confers.
  • and predominantly social health systems, working to a high standard with the same values in comparable structures and under similar pressures, adhering to similar legislation and other influences.
  • Globally regarded genomic and broader scientific and technology capabilities but with similar challenges of innovation and adoption that has limited the transfer of this to comparable achievements in commercialisation of this knowledge capital.
  • Public engaged in health and research with a drive to more engaged in their care and adopt new interventions of value.
  • A demonstrated ability to successfully deliver major national and multinational programmes under collaborative structures.
  • Existing health data infrastructures that can be utilised and further developed for personalised medicine.

Chair

Gordon McVie

Gordon McVie

Co-Chair, EAPM

Panel

Research and reproducibility in the translational process of Personalized Medicine; the role of European Research Infrastructures

Antonio Andreu

Antonio Andreu

Scientific Director, EATRIS

Gary Saunders

Gary Saunders

ELIXIR

Mariya Gabriel

Mariya Gabriel

Commissioner, Digital Economic and Society, European Commission